Oncology PracticePET-CT accurately predicts survival of follicular lymphoma patientsJune 9, 2014Lymphoma & Plasma Cell DisordersFollicular Lymphoma
Hematology TimesAgricultural chemicals and the risk of NHLMay 8, 2014Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaFollicular Lymphoma
Oncology PracticeYounger men with goiter at higher risk for thyroid cancersApril 10, 2014Head & Neck/Thyroid CancersFollicular Lymphoma
Hematology TimesEC approves SC formulation of rituximabMarch 31, 2014Lymphoma & Plasma Cell DisordersPharmacyFollicular Lymphoma
Hematology TimesVorinostat demonstrates antitumor activity in FLMarch 26, 2014Lymphoma & Plasma Cell DisordersFollicular Lymphoma
Hematology TimesAnticancer drugs might promote lymphomaMarch 25, 2014Lymphoma & Plasma Cell DisordersFollicular Lymphoma
Hematology TimesIdelalisib more effective in CLL, iNHL than MCLMarch 11, 2014Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaFollicular Lymphoma
Hematology TimesRIT can improve transplant outcomes in NHL, CLLMarch 7, 2014Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersTransplantationNon-Hodgkin LymphomaFollicular Lymphoma
Hematology TimesTeam identifies mutations that may drive FLJanuary 11, 2014Lymphoma & Plasma Cell DisordersFollicular Lymphoma
Oncology PracticeImmune microenvironment linked to prognosis of follicular lymphomaAugust 6, 2013Lymphoma & Plasma Cell DisordersFollicular Lymphoma
Oncology PracticeBendamustine-Rituximab Doubles Progression-Free Survival in Indolent LymphomasJune 3, 2012Lymphoma & Plasma Cell DisordersFollicular Lymphoma
Oncology PracticeThe Oncology Report Guide to Cancer Drugs and Devices in 2011February 21, 2012Patient & Survivor CareFollicular Lymphoma
Hematology TimesIs the US running too many T-cell lymphoma trials?February 2, 2012Lymphoma & Plasma Cell DisordersFollicular Lymphoma
Oncology PracticePregnant Women With Lymphoma Can Have Good OutcomesJanuary 12, 2012Lymphoma & Plasma Cell DisordersFollicular Lymphoma
Oncology PracticeObinutuzumab Equals Rituximab in Relapsed Indolent NHLDecember 13, 2011Lymphoma & Plasma Cell DisordersFollicular Lymphoma
